Mouze Liu
Overview
Explore the profile of Mouze Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
136
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin C, Ma R, Zeng X, Zhang B, Cao T, Jiao S, et al.
Front Pharmacol
. 2024 Dec;
15:1423214.
PMID: 39669197
Background: High-dose methotrexate (HD-MTX) is commonly employed in the treatment of malignant tumors in children and young adults due to its distinctive therapeutic efficacy. Nonetheless, the systemic exposure to MTX...
2.
Liu W, Xiao C, Luo J, Liu M, Sun B, Luo Z
Int Immunopharmacol
. 2024 Apr;
133:112142.
PMID: 38669948
Background: Identifying patients who can benefit from immune checkpoint inhibitors (ICIs) is a critical challenge in immunotherapy. This study aimed to investigate the association between fat mass and obesity-associated protein...
3.
Sun B, Ma S, Xiao F, Luo J, Liu M, Liu W, et al.
BMC Cardiovasc Disord
. 2023 May;
23(1):279.
PMID: 37254053
Aim: The anticoagulation effect of warfarin is usually evaluated by percentage of time in therapeutic range (PTTR), which is negatively correlated with the risk of warfarin adverse reactions. This study...
4.
Lai J, Ouyang J, Lin W, Liu M, Yang Y, Wang R, et al.
Front Genet
. 2022 Sep;
13:916281.
PMID: 36105108
Previous studies have demonstrated that is closely related to insulin resistance, metabolic disorders and vascular diseases. Recently, it was reported that a 33 bp variable number of tandem repeats (VNTR)...
5.
Yang Y, Qiu W, Meng Q, Liu M, Lin W, Yang H, et al.
Front Cardiovasc Med
. 2021 Oct;
8:728976.
PMID: 34651026
Diabetic vascular complications are one of the main causes of death and disability. Previous studies have reported that genetic variation is associated with diabetic vascular complications. In this study, we...
6.
Liu W, Wang Y, Luo J, Liu M, Luo Z
Front Immunol
. 2021 Feb;
11:586760.
PMID: 33603734
Cancer is an important threat to public health because of its high morbidity and mortality. In recent decades, immune checkpoint inhibitors (ICIs) have ushered a new therapeutic era in clinical...
7.
Liu W, Liu Y, Ma F, Sun B, Wang Y, Luo J, et al.
Cancer Manag Res
. 2021 Feb;
13:765-771.
PMID: 33536784
Background: Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for patients with advanced non-small-cell lung cancer (aNSCLC), but immune-related adverse events (irAEs) have been evidenced curtailed the clinical use...
8.
Zhang S, Song S, Luo X, Liu J, Liu M, Li W, et al.
Basic Clin Pharmacol Toxicol
. 2021 Jan;
128(6):822-830.
PMID: 33411948
Acute paraquat poisoning resulting from multiple organ failure usually has a high mortality rate. Liver and kidney, as the key oranges of paraquat detoxification and elimination, their injuries may suppress...
9.
Zhao C, Yu N, Li W, Cai H, Liu M, Hu Y, et al.
Front Pharmacol
. 2020 Oct;
11:549377.
PMID: 33071780
"Lipotoxicity" induced by free fatty acids (FAs) plays a central role in the pathogenesis of many metabolic diseases, with few treatment options available today. Hydrogen sulfide (HS), a novel gaseous...
10.
He F, Sun B, Li L, Liu M, Lin W, Liu L, et al.
Ann Transl Med
. 2020 May;
8(7):437.
PMID: 32395481
Background: Our previous studies have found that single nucleotide polymorphisms (SNPs) of () are related to the hypotensive effects of calcium-channel blockers (CCBs) and angiotensin-converting enzyme (ACE) inhibitors. In this...